@article {ConstantinoP2.030作者= {Tawnya Constantino教授Barry Gidal和斯科特·明茨托德·格林奈尔和大卫·布卢姆和海龙程},title ={标记的骨代谢和脂质代谢在Eslicarbazepine醋酸(ESL)单药治疗癫痫病患者采取或不采取药物(EIAEDs)基线(提单)(P2.030)},体积={86}={16}补充数量,elocation-id = {P2.030} ={2016},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:评估ESL单一疗法对实验室的影响骨代谢和脂质代谢标记,以及转换从一个环境影响评价的影响(卡马西平、苯妥英)ESL单一疗法。首页背景:aed,尤其是EIAEDs,会导致骨代谢和脂类代谢的变化导致骨质疏松和心血管疾病的风险增加。方法:这是一个探索性的,因果分析的数据来自两个III期ESL单一疗法试验(093 - 045;-046),从一个开放的扩展研究(OLE;-050)。患者(16 - 70年;部分性癫痫发作1 - 2 aed)控制不好收到ESL 1600毫克或1200毫克每日一次(QD) 16周(10周单一疗法)其次是OL ESL(800 - 2400毫克)长达12个月。实验室骨代谢和脂质代谢标志物以提单,18周,OL 12个月。结果:365例带> = 1 ESL剂量(1600毫克或1200 mg QD);130 (36 [percnt])了环评在提单(+环境影响评价);(percnt)和235年(64年)没有(-EIAED)。 180/274 patients who entered the OLE completed 1 year of treatment. At BL, most markers of bone turnover and lipid metabolism were higher in the +EIAED than -EIAED group. After 18 weeks, changes in bone turnover markers were variable, but after 12 months, most markers were increased versus BL. At both time points, all lipid markers showed increases versus BL in the -EIAED group, but most markers showed reductions versus BL in the +EIAED group. Conclusions: After a year of OL ESL monotherapy, most markers of bone turnover were increased versus BL; the impact of BL EIAED use was variable. In -EIAED patients, all lipid markers increased during ESL monotherapy; in the +EIAED group, most showed reductions. This suggests an intermediate effect of ESL on these markers, consistent with a mild-to-moderate degree of enzyme induction. Study Supported by Sunovion Pharmaceuticals Inc.Disclosure: Dr. Constantino has received personal compensation for activities with Sunovion Pharmaceuticals Inc. Dr. Gidal has received personal compensation for activities with Upsher-Smith. Dr. Mintzer has received personal compensation for activities with UCB Pharma, Sunovion, Upsher-Smith Laboratories, Pfizer Inc., SK Pharmaceuticals, Vertex Pharmaceuticals, and Eisai Inc. as a speaker and/or consultant. Dr. Grinnell has received personal compensation for activities with Sunovion Pharmaceuticals. Dr. Blum has received personal compensation for activities with Sunovion Pharmaceuticals Inc. as an employee. Dr. Cheng has received personal compensation for activities with Sunovian Pharmaceuticals, Inc.Sunday, April 17 2016, 8:30 am-5:30 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/86/16_Supplement/P2.030}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }